TY - JOUR
T1 - Thrombocytopenia after transcatheter aortic valve implantation
AU - Tirado-Conte, Gabriela
AU - Panagides, Vassili
AU - Vergara-Uzcategui, Carlos E.
AU - Fernandez, Gabriela Veiga
AU - Vílchez, Jean Paul
AU - Cepas-Guillén, Pedro
AU - Oteo, Juan Francisco
AU - Barrero, Alejandro
AU - Marroquin, Luis
AU - Farjat-Pasos, Julio I.
AU - Arslani, Ketina
AU - Jimenez-Quevedo, Pilar
AU - Núñez-Gil, Iván
AU - Mejia-Renteria, Hernan
AU - Hernández, José M. de la Torre
AU - Gil, José Luis Díez
AU - Regueiro, Ander
AU - Amat-Santos, Ignacio
AU - Fernández-Ortiz, Antonio
AU - Eid-Lidt, Guering
AU - de Backer, Ole
AU - Rodés-Cabau, Josep
AU - Nombela-Francoa, Luis
PY - 2025
Y1 - 2025
N2 - Introduction and objectives: Thrombocytopenia frequently occurs after transcatheter aortic valve implantation (TAVI) but its impact is poorly understood. We aimed to analyze the incidence, clinical impact, and predictors of acquired thrombocytopenia after TAVI.Methods: This retrospective multicenter registry included 3913 patients undergoing TAVI with a baseline platelet count of > 100 *109/L. Acquired thrombocytopenia was defined as a decrease in baseline platelet count of > 50% (early nadir < 3 days and late nadir > 4 days) post-TAVI. The primary endpoint was 30-day all-cause mortality and secondary endpoints were procedural safety and 2-year all-cause mortality.Results: The incidence of acquired thrombocytopenia was 14.8% (early nadir: 61.5%, late nadir: 38.5%). Thirty-day mortality occurred in 112 (3.0%) patients and was significantly higher in those with thrombocytopenia (8.5% vs 2.0%, adjusted OR, 2.3; 95%CI, 1.3-4.2). Procedural safety was lower and 2-year mortality was higher in patients with thrombocytopenia vs those without (52.1 vs 77.0%; P < .001, and 30.2% vs 16.8%; HR, 2.2, 95%IC, 1.3-2.7) and especially in those with late nadir thrombocytopenia (45.8% vs 54.5%; P = .056, and 38.6% vs 23.8%, HR, 2.1; 95%CI, 1.5-2.9). Independent predictors of thrombocytopenia comprised baseline and procedural factors such as body surface area, absence of diabetes, poorer renal function, peripheral vascular disease, nontransfemoral access, vascular complications, type of transcatheter heart valve, and earlier TAVI procedures.Conclusions: Acquired thrombocytopenia was common (15%) after TAVI and was associated with increased short-and mid-term mortality and decreased procedural safety. Moreover, late thrombocytopenia compared with early thrombocytopenia was associated with significantly worse clinical outcomes. Further investigations are needed to elucidate the etiologic mechanisms behind these findings. (C) 2024 Sociedad Espanola de Cardiologia. Published by Elsevier Espana, S.L.U. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
AB - Introduction and objectives: Thrombocytopenia frequently occurs after transcatheter aortic valve implantation (TAVI) but its impact is poorly understood. We aimed to analyze the incidence, clinical impact, and predictors of acquired thrombocytopenia after TAVI.Methods: This retrospective multicenter registry included 3913 patients undergoing TAVI with a baseline platelet count of > 100 *109/L. Acquired thrombocytopenia was defined as a decrease in baseline platelet count of > 50% (early nadir < 3 days and late nadir > 4 days) post-TAVI. The primary endpoint was 30-day all-cause mortality and secondary endpoints were procedural safety and 2-year all-cause mortality.Results: The incidence of acquired thrombocytopenia was 14.8% (early nadir: 61.5%, late nadir: 38.5%). Thirty-day mortality occurred in 112 (3.0%) patients and was significantly higher in those with thrombocytopenia (8.5% vs 2.0%, adjusted OR, 2.3; 95%CI, 1.3-4.2). Procedural safety was lower and 2-year mortality was higher in patients with thrombocytopenia vs those without (52.1 vs 77.0%; P < .001, and 30.2% vs 16.8%; HR, 2.2, 95%IC, 1.3-2.7) and especially in those with late nadir thrombocytopenia (45.8% vs 54.5%; P = .056, and 38.6% vs 23.8%, HR, 2.1; 95%CI, 1.5-2.9). Independent predictors of thrombocytopenia comprised baseline and procedural factors such as body surface area, absence of diabetes, poorer renal function, peripheral vascular disease, nontransfemoral access, vascular complications, type of transcatheter heart valve, and earlier TAVI procedures.Conclusions: Acquired thrombocytopenia was common (15%) after TAVI and was associated with increased short-and mid-term mortality and decreased procedural safety. Moreover, late thrombocytopenia compared with early thrombocytopenia was associated with significantly worse clinical outcomes. Further investigations are needed to elucidate the etiologic mechanisms behind these findings. (C) 2024 Sociedad Espanola de Cardiologia. Published by Elsevier Espana, S.L.U. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
KW - Tavi
KW - Thrombocytopenia
KW - Vascular complications
U2 - 10.1016/j.rec.2024.08.003
DO - 10.1016/j.rec.2024.08.003
M3 - Journal article
C2 - 39251129
SN - 1885-5857
VL - 78
SP - 347
EP - 357
JO - Revista espanola de cardiologia (English ed.)
JF - Revista espanola de cardiologia (English ed.)
IS - 4
ER -